Inhibitory effects of sanguinarine on human liver cytochrome P450 enzymes

Food and Chemical Toxicology

Volumn 56, Issue , 2013, Pages 392-397

  Qi, Xiao Yi ^a   Liang, Si Cheng ^b,c   Ge, Guang Bo ^b   Liu, Yong ^b   Dong, Pei Pei ^a   Zhang, Jiang Wei ^b   Wang, Ao Xue ^a   Hou, Jie ^a   Zhu, Liang Liang ^b   Yang, Ling ^b   Tu, Cai Xia ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

^c Dalian Administration of Animal Health by Supervision   (China)

Author keywords

Cytochrome P450 enzyme; Drug drug interaction; Human liver microsomes; Sanguinarine; Time dependent inhibition

Indexed keywords

CLOMETHIAZOLE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; FURAFYLLINE; KETOCONAZOLE; MONTELUKAST; QUINIDINE; SANGUINARINE; SULFAPHENAZOLE; TRANYLCYPROMINE;

ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME;

ARYL HYDROCARBON HYDROXYLASES; BENZOPHENANTHRIDINES; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; ISOQUINOLINES; KINETICS; LIVER; MICROSOMES, LIVER; NADP;

EID: 84875650985     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2013.02.054     Document Type: Article

References (32)

1. Austin R.P., Barton P., Cockroft S.L., Wenlock M.C., Riley R.J. The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metab. Dispos. 2002, 30:1497-1503.
2. Banerjee B.D., Seth V., Koner B.C., Ahmed R.S., Sharma M., Grover S.S., Rautala R.S., Avasthi R., Pasha S.T. Evaluation of oxidative stress in some cases of argimone oil poisoning during a recent outbreak of epidemic dropsy in India. Int. J. Environ. Health Res. 2000, 10:341-346.
3. Deroussent A., Ré M., Hoellinger H., Cresteil T. Metabolism of sanguinarine in human and in rat: characterization of oxidative metabolites produced by human CYP1A1 and CYP1A2 and rat liver microsomes using liquid chromatography-tandem mass spectrometry. J. Pharm. Biomed. Anal. 2010, 52:391-397.
4. Eruvaram N.R., Das M. Phenotype of hepatic xenobiotic metabolizing enzymes and CYP450 isoforms of sanguinarine treated rats: effect of P450 inducers on its toxicity. Toxicol. Mech. Methods 2009, 19:510-517.
5. Evans W.E., Relling M.V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999, 286:487-491.
6. Fang Z.Z., Zhang Y.Y., Ge G.B., Huo H., Liang S.C., Yang L. Time-dependent inhibition (TDI) of CYP3A4 and CYP2C9 by noscapine potentially explains clinical noscapine-warfarin interaction. Br. J. Clin. Pharmacol. 2010, 69:193-199.
7. Guengerich F.P. Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J. 2006, 8:E101-E111.
8. Karp J.M., Rodrigo K.A., Pei P., Pavlick M.D., Andersen J.D., McTigue D.J., Fields H.W., Mallery S.R. Sanguinarine activates polycyclic aromatic hydrocarbon associated metabolic pathways in human oral keratinocytes and tissues. Toxicol. Lett. 2005, 158:50-60.
9. Keller K.A., Meyer D.L. Reproductive and developmental toxicological evaluation of sanguinaria extract. J. Clin. Dent. 1989, 1:59-66.
10. Kosina P., Walterová D., Ulrichová J., Lichnovský V., Stiborová M., Rýdlová H., Vicar J., Krecman V., Brabec M.J., Simánek V. Sanguinarine and chelerythrine: assessment of safety on pigs in 90days feeding experiment. Food. Chem. Toxicol. 2004, 42:85-91.
11. Lin J.H., Lu A.Y. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol. Rev. 1997, 49:403-449.
12. Lu P., Schrag M.L., Slaughter D.E., Raab C.E., Shou M., Rodrigues A.D. Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab. Dispos. 2003, 31:1352-1360.
13. Ma Q., Lu A.Y. Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol. Rev. 2011, 63:437-459.
14. Mackraj I., Govender T., Gathiram P. Sanguinarine. Cardiovasc. Ther. 2008, 26:75-83.
15. Malikova J., Zdarilova A., Hlobilkova A. Effects of sanguinarine and chelerythrine on the cell cycle and apoptosis. Biomed. Pap. Med. Fac. Univ. Palacky. Olomouc. Czech. Republic 2006, 150:5-12.
16. Moore L.B., Goodwin B., Jones S.A., Wisely G.B., Serabjit-Singh C.J., Willson T.M., Collins J.L., Kliewer S.A. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc. Natl. Acad. Sci. USA 2000, 97:7500-7502.
17. Murray M. Mechanisms of inhibitory and regulatory effects of methylenedioxyphenyl compounds on cytochrome P450-dependent drug oxidation. Curr. Drug Metab. 2000, 1:67-84.
18. Obach R.S. Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression. J. Pharmacol. Exp. Ther. 2000, 294:88-95.
19. Obach R.S., Walsky R.L., Venkatakrishnan K. Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions. Drug Metab. Dispos. 2007, 35:246-255.
20. Pica F., Balestrieri E., Serafino A., Sorrentino R., Gaziano R., Moroni G., Moroni N., Palmieri G., Mattei M., Garaci E., Sinibaldi-Vallebona P. Antitumor effects of the benzophenanthridine alkaloid sanguinarine in a rat syngeneic model of colorectal cancer. Anticancer Drugs 2012, 23:32-42.
21. Reddy N.P., Das M. Interaction of sanguinarine alkaloid, isolated from argemone oil, with hepatic cytochrome p450 in rats. Toxicol. Mech. Methods 2008, 18:635-643.
22. Shenolikar I.S., Rukmini C., Krishnamachari K.A., Satyanarayana K. Sanguinarine in the blood and urine of cases of epidemic dropsy. Food. Cosmet. Toxicol. 1974, 12:699-702.
23. Shimada T., Yamazaki H., Mimura M., Inui Y., Guengerich F.P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 1994, 270:414-423.
24. Shimada T. Xenobiotic-metabolizing enzymes involved in activation and detoxification of carcinogenic polycyclic aromatic hydrocarbons. Drug Metab. Pharmacokinet. 2006, 21:257-276.
25. Sridhar J., Liu J., Foroozesh M., Klein Stevens C.L. Inhibition of cytochrome P450 enzymes by quinones and anthraquinones. Chem. Res. Toxicol. 2012, 25:357-365.
26. Taylor S., Harker A. Modification of the ultrafiltration technique to overcome solubility and non-specific binding challenges associated with the measurement of plasma protein binding of corticosteroids. J. Pharm. Biomed. Anal. 2006, 41:299-303.
27. Tsukamoto H., Kondo S., Mukudai Y., Nagumo T., Yasuda A., Kurihara Y., Kamatani T., Shintani S. Evaluation of anticancer activities of benzo[c]phenanthridine alkaloid sanguinarine in oral squamous cell carcinoma cell line. Anticancer Res. 2011, 31:2841-2846.
28. Vecera R., Klejdus B., Kosina P., Orolin J., Stiborová M., Smrcek S., Vicar J., Dvorák Z., Ulrichová J., Kubán V., Anzenbacher P., Simánek V. Disposition of sanguinarine in the rat. Xenobiotica 2007, 37:549-558.
29. Vrba J., Kosina P., Ulrichová J., Modrianský M. Involvement of cytochrome P450 1A in sanguinarine detoxication. Toxicol. Lett. 2004, 151:375-387.
30. Zdarilová A., Vrzal R., Rypka M., Ulrichová J., Dvorák Z. Investigation of sanguinarine and chelerythrine effects on CYP1A1 expression and activity in human hepatoma cells. Food. Chem. Toxicol. 2006, 44:242-249.
31. Zhang Q.Y., Dunbar D., Ostrowska A., Zeisloft S., Yang J., Kaminsky L.S. Characterization of human small intestinal cytochromes P-450. Drug Metab. Dispos. 1999, 27:804-809.
32. Zhang J.W., Liu Y., Cheng J., Li W., Ma H., Liu H.T., Sun J., Wang L.M., He Y.Q., Wang Y., Wang Z.T., Yang L. Inhibition of human liver cytochrome P450 by star fruit juice. J. Pharm. Pharm. Sci. 2007, 10:496-503.